Clinical trials
Terminated Thyroid Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 47 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| M.D. Anderson Cancer Center | 4 |
| Medstar Health Research Institute | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| ABM Therapeutics Corporation | 1 |
| Actym Therapeutics, Inc. | 1 |
| Calando Pharmaceuticals | 1 |
| Celgene | 1 |
| Dana-Farber Cancer Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thyroid Neoplasms | 47 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Melanoma | 10 |
| Carcinoma, Medullary | 8 |
| Thyroid Carcinoma, Anaplastic | 8 |
| Breast Neoplasms | 7 |
| Neoplasm Metastasis | 7 |
| Ovarian Neoplasms | 7 |
| Colorectal Neoplasms | 6 |
| Pancreatic Neoplasms | 6 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.